התפתחות דרמטית בסרטן הלבלב: טיפול חמלה למוטציית KRAS

For decades, the KRAS mutation was considered one of the toughest challenges in oncology—a target that researchers simply couldn't drug. However, the landscape is rapidly changing, particularly for pancreatic cancer patients.

In a recent advanced clinical trial (Phase 3) published in the medical journal NEJM, the drug showed impressive results. Patients who received the new targeted therapy Daraxonrasib lived, on average (median), twice as long as those on standard chemotherapy—13.2 months compared to 6.6 months.

Following these remarkable results, a program has been opened that allows selected eligible patients to access Daraxonrasib through an Expanded Access (Compassionate Use) program, even before its official approval.

If you or a loved one are dealing with pancreatic cancer, here is a clear explanation of what this development means, who is eligible, and what the logistical process actually looks like.

What is a KRAS Mutation?

KRAS is a gene that acts like an on/off switch in cell signaling. When mutated, it stays stuck in the "on" position, causing cells to grow and divide uncontrollably, leading to cancer. It is highly prevalent in pancreatic cancer. For a long time, its shape made it nearly impossible to target with drugs, but new therapies like Daraxonrasib are finally cracking this code.

What is Compassionate Use (Expanded Access)?

Expanded Access, often called Compassionate Use, is a potential pathway for a patient with an immediately life-threatening condition to gain access to an investigational medical product for treatment outside of clinical trials when no comparable or satisfactory alternative therapy options are available. The pharmaceutical company provides the experimental drug before it receives official FDA approval.

Who is Eligible for the Program?

According to the company's current criteria, the compassionate use program is strictly designed for patients who meet the following conditions:

• Diagnosed with pancreatic cancer.
• Have a confirmed KRAS mutation.
• Have already completed at least one line of therapy (chemotherapy).
• Are in good functional status (able to carry out daily activities).

The Logistics: Direct and Indirect Costs

While the experimental drug itself is typically provided at no cost, there are significant indirect logistics to consider:

• Location: At the time of writing, access generally requires evaluation and treatment through participating US centers.
• Medical Consultation: Patients must be examined by an American oncologist, which may require paying privately for the consultation if out of network or abroad.
• Timeframe: Patients need to stay in the US for about two to three weeks until the drug is officially supplied and the initial process is safely monitored.

A Crucial Time Window

FDA approval is widely anticipated in the coming months, although timelines may change. Once approved, the compassionate use window will likely close. The drug will then become commercially available and could be imported, but it will likely come with a high price tag until it is included in local health baskets.

What Are Your Next Steps?

If you meet the criteria mentioned above, time is of the essence. Here is what you can do right now:

1. Talk to your oncologist: Bring up Daraxonrasib and the compassionate use program. If you aren't sure how to start this conversation, use our guide on discussing new treatments with your doctor.
2. Ask about international connections: Many leading oncologists have direct relationships with medical centers and researchers in the US. They can often facilitate the introduction and connect you with the right American physician to start the process.
3. Know your tumor's genetics: To find out if this treatment is right for you, a genetic sequencing test (molecular profiling) must be done on a sample of the tumor (usually from a biopsy). If you haven't done this yet, ask your doctor about getting tested for the KRAS mutation.

Reference: O'Reilly E.M., Wainberg Z.A., et al. "Daraxonrasib or Chemotherapy in Previously Treated Metastatic Pancreatic Cancer," NEJM, May 2026. (DOI: 10.1056/NEJMoa2605555, Trial: NCT06625320).

How to Find KRAS Clinical Trials

Even if you are not eligible for Expanded Access, there may be ongoing clinical trials investigating KRAS-targeted therapies. TrialFinder can help you identify studies that match your diagnosis, treatment history, and genetic profile.

Medical disclaimer: This article is intended for educational purposes only and should not replace professional medical advice. Eligibility for Expanded Access programs is determined by the treating physicians, the sponsoring company, and applicable regulations.